Checkpoint Therapeutics - CKPT Stock Forecast, Price & News

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics Stock Performance

NASDAQ:CKPT opened at $1.29 on Monday. The company's fifty day moving average is $1.15 and its two-hundred day moving average is $1.52. Checkpoint Therapeutics has a 52-week low of $0.96 and a 52-week high of $4.64.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.09). Checkpoint Therapeutics had a negative net margin of 26,592.46% and a negative return on equity of 173.15%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.07 million. Research analysts predict that Checkpoint Therapeutics will post -0.7 EPS for the current year.

Wall Street Analyst Weigh In

Separately, B. Riley reissued a "buy" rating and set a $7.00 price target on shares of Checkpoint Therapeutics in a report on Thursday, July 14th.

Insider Buying and Selling

In related news, CEO James F. Oliviero III sold 228,000 shares of the business's stock in a transaction on Friday, June 17th. The shares were sold at an average price of $1.09, for a total value of $248,520.00. Following the sale, the chief executive officer now directly owns 2,610,003 shares of the company's stock, valued at approximately $2,844,903.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 264,000 shares of company stock valued at $288,060 over the last ninety days. Insiders own 5.10% of the company's stock.